Zhongzheng Pharmaceutical

Kexing Biopharm is a high-tech biopharmaceutical enterprise integrating R&D, production, and sales. As a pioneer of modern biopharmaceuticals in China, the company adheres to the philosophy of lean pharmaceutical manufacturing, lean medication, and health protection, and is committed to promoting the development of high-quality biologics and the continuous enhancement of their clinical value, creating more possibilities for patient health.
The company has over 30 years of mature production management experience, strong technical strength, and a comprehensive quality management system. It has established three major production bases in Guangdong and Shandong, and has successfully built multiple domestically and internationally leading technology platforms, including a prokaryotic expression technology platform, a eukaryotic expression technology platform, a long-acting recombinant protein technology platform, and a microecology technology platform.
Kexing Biopharm has successively obtained 13 new drug certificates, owns 2 Class 1 new drugs of China, and 2 patented varieties, and has formed unique advantages in fields such as antivirals, blood, digestion, oncology, and immunology. Core products, such as recombinant human interferon α1b for injection (Sai Ruo Jin) and recombinant human erythropoietin injection (CHO cell) (Yi Pu Ding), have ranked among the industry forefront in terms of popularity, reputation, and market share.
The company actively explores the international biopharmaceutical market, and its products have achieved market access and sales in more than 30 countries and regions, including Brazil, South Korea, Egypt, Indonesia, and Peru. According to a report by Pharmaceutical Economic News, "In 2014, Kexing Biopharm became China's *** EPO preparation exporter."